GUARDANT COMPLETE™

Guardant Treatment Selection and Monitoring

Get liquid and tissue comprehensive genomic profiling results, including PD-L1, and measurement of treatment response —all with a single checkbox.

One checkbox includes three Guardant tests*

Guardant Treatment Selection and Monitoring *Order from the Test Requisition Form*	Liquid treatment selection	Tissue treatment selection	Liquid treatment monitoring
	FDA APPROVED GUARDANT360 CDx	GUARDANT360 TissueNext™ Including PD-L1 ^	GUARDANT360 Response™
	Identify actionable biomarkers in newly diagnosed patients to inform treatment selection	Find actionable information when tissue testing is appropriate	Measure changes in circulating tumor DNA (ctDNA) to assess early response to treatment#
	7-day turnaround	2-to-3-week turnaround	Under 2-week turnaround

*Guardant360 TissueNext will only be run after a confirmatory Test Requisition Form is signed, affirming the medical necessity for the test once the liquid results are known. Patients who have a negative Guardant360 CDx test result for an indicated companion diagnostic biomarker should be reflexed to tissue biopsy testing using an FDA approved tumor tissue test, if feasible. For the complete intended use statement, including companion diagnostic indications, please see the Guardant360 CDx Technical Information: Guardant360CDx.com/technicalinfo.
^PD-L1 is automatically included but providers can opt out by checking the "select to remove PD-L1" box on the Guardant Health Test Requisition Form.
#Guardant360 Response is a single time point test to assess early treatment response. Guardant Health will follow up 6 weeks after the Guardant360 CDx test is reported to fulfill your Guardant360 Response order.

Important Note: Guardant360 TissueNext and Guardant360 Response tests were developed, and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. These tests have not been cleared or approved by the U.S. FDA.

Client Services: 1.855.698.8887 • **clientservices@guardanthealth.com**